中国医药科学
中國醫藥科學
중국의약과학
CHINA MEDICINE AND PHARMACY
2013年
17期
100-101,125
,共3页
食管癌%化疗%放疗%替吉奥%奈达铂%顺氯氨铂%5-氟尿嘧啶
食管癌%化療%放療%替吉奧%奈達鉑%順氯氨鉑%5-氟尿嘧啶
식관암%화료%방료%체길오%내체박%순록안박%5-불뇨밀정
Esophageal cancer%Chemotherapy%Radiotherapy%S-1%Nedaplatin%Cisplatin%Fluorouracil
目的探讨替吉奥+奈达铂（S1N）、5-氟尿嘧啶+顺铂（FP）方案加同步放疗治疗中晚期食管癌的疗效，毒副反应及耐受性观察。方法62例中晚期食管癌患者随机分为两组：试验组（S1N方案加同步放疗）30例，对照组（FP方案加同步放疗）32例。放疗均采用钴60-γ线常规分割照射。结果 S1N化放组、FP化放组有效率分别为86.7%、62.5%。S1N化放组的有效率高，差异有统计学意义（P＜0.05）。S1N化放组、FP化放组1年生存率分别为73.3%、59.4%，差异无统计学意义（P＞0.05）。主要副反应为消化道反应、骨髓抑制，放射性食管炎。FP组消化道反应、静脉炎较重，比较差异有统计学意义（P＜0.05）。S1N组骨髓抑制较重，差异无统计学意义（P＞0.05）。患者可以耐受，无治疗相关性死亡。结论两方案同步放化疗治疗均可用于中晚期食管癌的综合治疗。
目的探討替吉奧+奈達鉑（S1N）、5-氟尿嘧啶+順鉑（FP）方案加同步放療治療中晚期食管癌的療效，毒副反應及耐受性觀察。方法62例中晚期食管癌患者隨機分為兩組：試驗組（S1N方案加同步放療）30例，對照組（FP方案加同步放療）32例。放療均採用鈷60-γ線常規分割照射。結果 S1N化放組、FP化放組有效率分彆為86.7%、62.5%。S1N化放組的有效率高，差異有統計學意義（P＜0.05）。S1N化放組、FP化放組1年生存率分彆為73.3%、59.4%，差異無統計學意義（P＞0.05）。主要副反應為消化道反應、骨髓抑製，放射性食管炎。FP組消化道反應、靜脈炎較重，比較差異有統計學意義（P＜0.05）。S1N組骨髓抑製較重，差異無統計學意義（P＞0.05）。患者可以耐受，無治療相關性死亡。結論兩方案同步放化療治療均可用于中晚期食管癌的綜閤治療。
목적탐토체길오+내체박（S1N）、5-불뇨밀정+순박（FP）방안가동보방료치료중만기식관암적료효，독부반응급내수성관찰。방법62례중만기식관암환자수궤분위량조：시험조（S1N방안가동보방료）30례，대조조（FP방안가동보방료）32례。방료균채용고60-γ선상규분할조사。결과 S1N화방조、FP화방조유효솔분별위86.7%、62.5%。S1N화방조적유효솔고，차이유통계학의의（P＜0.05）。S1N화방조、FP화방조1년생존솔분별위73.3%、59.4%，차이무통계학의의（P＞0.05）。주요부반응위소화도반응、골수억제，방사성식관염。FP조소화도반응、정맥염교중，비교차이유통계학의의（P＜0.05）。S1N조골수억제교중，차이무통계학의의（P＞0.05）。환자가이내수，무치료상관성사망。결론량방안동보방화료치료균가용우중만기식관암적종합치료。
Objective To evaluate the efficacy and safety of S-1 plus nedaplatin and combined with concurrent radiotherapy in the treatment of terminal esophageal cancer. Methods From June 2009 to December 2011, 62 patients with advanced squamous cell carcinoma of the esophagus were divided into two groups of the experimental group (30 cases) and the control group (32 cases). Radiotherapy was used cobalt 60-γ-line conventional fractionated irradiation. Results The overall response rate (CR+PR) of the experimental group and the control group were 86.7% and 62.5%respectively (P<0.05).The year survival rates of S1N chemoradiotherapy group and FP chemoradiotherapy group were 73.3%and 59.4%, the difference was not statistically significant (P>0.05). The main toxicities were nausea, vomting, marrow depression and radioactive esophagitis. The control group patients had more toxicities. All of them complete treating plan. Conclusion The short term curative effect of S-1 and nedaplatin in combination with radiotherapy is feasible for medium term and terminal esophageal cancer, and toxicity is tolerable.
